BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST

BridgeBio Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,533570.12681.1375.94376.69393.77
Short-Term Investments
5.4917.36-58.9595.23442.89
Cash & Short-Term Investments
1,539587.48681.1434.88471.92836.66
Cash Growth
138.23%-13.74%56.62%-7.85%-43.59%37.81%
Accounts Receivable
375.09139.444.721.7517.0819.75
Receivables
375.09139.444.721.7517.0819.75
Inventory
59.7226.75----
Prepaid Expenses
69.3938.4231.0424.3121.9232.27
Restricted Cash
0.550.550.1316.6537.930.18
Other Current Assets
15.13.7---
Total Current Assets
2,045797.75720.69477.59548.85888.86
Property, Plant & Equipment
20.7913.5212.7819.8425.2545.97
Long-Term Investments
47.7879.97143.751.6--
Other Intangible Assets
25.9228.0823.9326.3228.7144.93
Other Long-Term Assets
22.6916.7118.221.0320.2233.03
Total Assets
2,162936.03919.34546.38623.041,013

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
88.2636.239.6210.6611.5611.88
Accrued Expenses
320.14238.36124.08116.9795.54116.75
Current Portion of Long-Term Debt
548.43-----
Current Portion of Leases
1.996.194.514.133.684.94
Current Unearned Revenue
4.747.1914.66.18.16-
Other Current Liabilities
13.68-1.662.51.5
Total Current Liabilities
977.24287.97154.4143.84121.43135.07
Long-Term Debt
2,8131,8521,7211,7271,7081,704
Long-Term Leases
14.653.814.78.9812.2717.43
Long-Term Unearned Revenue
8.9713.0817.13.737.1-
Other Long-Term Liabilities
1.41855.27479.385.6319.5422.07
Total Liabilities
3,8153,0132,3771,8891,8681,878

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
0.210.20.20.180.160.15
Additional Paid-In Capital
2,1702,0581,9031,481938.7841.53
Retained Earnings
-4,194-3,821-3,096-2,561-1,918-1,437
Treasury Stock
-580.78-323.28-275-275-275-275
Comprehensive Income & Other
-0.10.010.010.03-0.33-0.13
Total Common Equity
-2,605-2,087-1,468-1,354-1,255-870.41
Minority Interest
8.8410.0310.2911.729.694.84
Shareholders' Equity
-1,654-2,077-1,458-1,343-1,245-865.58
Total Liabilities & Equity
2,162936.03919.34546.38623.041,013

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
3,3781,8621,7311,7401,7241,726
Net Cash (Debt)
-1,839-1,275-1,049-1,305-1,252-889.51
Net Cash Growth
------
Net Cash Per Share
-9.43-6.66-5.64-8.02-8.49-6.16
Filing Date Shares Outstanding
194.8193.86190.19175.83151.37147.61
Total Common Shares Outstanding
196194.77190.04175.08150.63147.34
Working Capital
1,067509.78566.29333.75427.43753.79
Book Value Per Share
-13.29-10.71-7.72-7.73-8.33-5.91
Tangible Book Value
-2,631-2,115-1,492-1,381-1,283-915.35
Tangible Book Value Per Share
-13.42-10.86-7.85-7.89-8.52-6.21
SEC Filings: 10-K · 10-Q